Found: 9
Select item for more details and to access through your institution.
Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 7, p. 1427, doi. 10.3390/jcm10071427
- By:
- Publication type:
- Article
The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
- Published in:
- Clinical Pharmacology & Therapeutics, 1996, v. 60, n. 3, p. 283, doi. 10.1016/S0009-9236(96)90055-7
- By:
- Publication type:
- Article
Nonparametric confidence intervals for Tmax in sequence-stratified crossover studies.
- Published in:
- Pharmaceutical Statistics, 2008, v. 7, n. 1, p. 9, doi. 10.1002/pst.253
- By:
- Publication type:
- Article
Comparison of models for average bioequivalence in replicated crossover designs.
- Published in:
- Pharmaceutical Statistics, 2006, v. 5, n. 3, p. 201, doi. 10.1002/pst.212
- By:
- Publication type:
- Article
Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis.
- Published in:
- Chronic Respiratory Disease, 2019, v. 16, n. 1, p. 1, doi. 10.1177/1479973119879678
- By:
- Publication type:
- Article
Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.
- Published in:
- Pulmonary Therapy, 2018, v. 4, n. 1, p. 103, doi. 10.1007/s41030-018-0056-8
- By:
- Publication type:
- Article
Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.
- Published in:
- 2019
- By:
- Publication type:
- corrected article
Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Post hoc Analysis of Clinical Outcomes in Placebo- and Pirfenidone-Treated Patients with IPF Stratified by BMI and Weight Loss.
- Published in:
- Respiration, 2022, v. 101, n. 2, p. 142, doi. 10.1159/000518855
- By:
- Publication type:
- Article